CTOs on the Move

Dianthus Therapeutics

www.dianthustx.com

 
Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dianthustx.com
  • 203 Crescent Street. Building 4 Suite 205
    Waltham, MA USA 02453
  • Phone: 252.227.7013

Executives

Name Title Contact Details

Similar Companies

Beacon Biotechnology

Beacon Biotechnology is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BlackThorn Therapeutics

BlackThorn Therapeutics is a neurobehavioral health company developing targeted therapeutics, informed by a deep understanding of brain and behavior relationships, to significantly improve patient outcomes.

Cogenix

Cogenix is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radix Biosolutions

Radix Biosolutions is a Georgetown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EpiVax Oncology

EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.